Published in Hepatitis Weekly, June 3rd, 2002
The company announced that it has received FDA clearance to begin clinical development of a novel anticancer drug, a human monoclonal antibody to TRAIL Receptor-1 (TRAIL-R1 mAb).
William A. Haseltine, PhD, chairman and CEO, said, "TRAIL-R1 mAb is an exciting new drug with a novel mechanism of action. It may eventually offer a promising therapeutic option for the treatment...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly